drugset / Trial / NCT00260832

Trial of Decitabine in Patients With Acute Myeloid Leukemia

NCT00260832

Phase 3 Completed 485 enrolled Eisai Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the results in older patients who have newly diagnosed or secondary acute myeloid leukemia (AML) and who are to either receive decitabine or patient's choice with the physician's advice of either cytarabine or supportive care medication.

Timeline

Start
2005-11
Primary completion
2009-10
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 20 mg/m2 Subcutaneous
Comparator Decitabine Small molecule 20 mg/m2 Intravenous